Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.

We studied the effects of nateglinide on serum adiponectin in 26 patients with type 2 diabetes mellitus. The changes in serum insulin at 30min significantly correlated with those in serum high-molecular weight adiponectin. Nateglinide may ameliorate hypoadiponectinemia as well as postprandial hyperglycemia in patients with type 2 diabetes mellitus.

Short term intensive insulin therapy improves insulin secretion significantly in type 2 diabetic patients.

To investigate the effects of short-term (1 week) intensive insulin therapy, on glycemic control, insulin secretion, and insulin sensitivity in type 2 diabetic patients, an open prospective study was conducted in sixteen type 2 diabetic patients receiving diet therapy alone or treatment with oral hypoglycemic agents. Of the study subjects, 8 patients were treated with insulin, the remaining 8 patients served as the control group. The metabolic parameters were evaluated once before treatment and once during one of the following treatments : glycemic control as measured by 1,5-anhydro-D-glucitol (1,5-AG) and area under curve of glucose (AUCglucose), insulin secretion as measured by area under curve of daily serum insulin (AUCinsulin), and insulin sensitivity as measured by the K index of the insulin tolerance test (K(ITT)).